Analysts at Canaccord Genuity downgraded AcelRx Pharmaceuticals ACRX from Buy to Hold.
The target price for AcelRx Pharmaceuticals has been lowered from $16.00 to $8.00.
AcelRx Pharmaceuticals shares have dropped 7.83% over the past 52 weeks, while the S&P 500 index has gained 17.39% in the same period.
AcelRx Pharmaceuticals' shares dropped 30.84% to $7.49 in pre-market trading.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in